Clinical Trial

Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-P) in the Treatment of CTD-ILD

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
To evaluate the safety and tolerability of IxCell hUC-MSC-P in the treatment of patients with connective tissue disease-related interstitial lung disease. To evaluate the efficacy, pharmacokinetics and immunogenicity of IxCell hUC-MSC-P in the treatment of connective tissue disease-associated interstitial lung disease (CTD-ILD).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-06.
Trial Details
NCT Number NCT06823063
Lead Sponsor Shanghai IxCell Biotechnology Co., LTD
Conditions CTD-ILD
Enrollment 18 participants
Start Date 2025-04-01
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-14